Abstract:Background: Publication of the Women's Health Initiative (WHI) trial results in 2002 significantly reduced physician and patient confidence in and acceptance of hormone replacement therapy (HRT) as an appropriate treatment option for menopause-associated vasomotor symptoms (VMS). This was true despite the fact that the WHI trial was a primary prevention study conducted in postmenopausal women and was not designed to evaluate the efficacy of HRT in the treatment of VMS. Objective: To review data from the WHI, including recent analyses, demonstrating the risks and benefits of HRT in postmenopausal women, to describe changes in menopause treatment guidelines and HRT use since publication of early WHI results nearly 6 years ago, and to identify opportunities for improving the quality of care in perimenopausal women. Summary: Early results from the WHI demonstrated that the risks of longterm HRT in postmenopausal women outweighed the benefits, leading study investigators to conclude that HRT should not be initiated or continued for the primary prevention of coronary heart disease (CHD) in postmenopausal women. Treatment guidelines published by several professional and managed care organizations continue to advocate the use of HRT for treatment of moderate-to-severe VMS. Nevertheless, physician and patient confidence in HRT has declined, as evidenced by a decrease in new HRT prescriptions and an increase in the discontinuation rate of HRT immediately following publication of the preliminary WHI results. Recent analyses demonstrate that the risk for CHD in postmenopausal women is largely dependent upon the age of the woman and the number of years since menopause, with a lower risk for CHD in women aged 50 to 59 years and in women who experienced menopause within the previous 10 years. The highest risk for CHD was evident in women aged 70 to 79 years and in women who experienced menopause 20 or more years ago. Although these data do not support the use of HRT as a primary prevention strategy in postmenopausal women, they do suggest the need to further evaluate the benefits and risks of HRT in perimenopausal women based on patient-specific characteristics, including age and time since menopause. Conclusion: Menopausal women present a unique opportunity for health care providers to improve the quality of care among women, not only as it relates to the treatment of VMS, but also as it relates to osteoporosis and cardiovascular disease, 2 common comorbidities in perimenopausal and postmenopausal women.

Exploring the potential for a set of UK hormone replacement therapy eligibility guidelines: A suggested proposal on the topic of venous thromboembolism

Optimising delivery systems for HRT

Systemic Estrogen Therapy and Thrombosis: A Call for Individualized Clinical Decision Making in the Acute Care Setting

Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective

Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative

[Estrogen replacement therapy: for whom, why and how?]

The evolving perspective of menopause management in the United Kingdom

POESIT recommendations on management of body-identical hormones in menopausal symptoms

Safety and benefit considerations for menopausal hormone therapy

Update on hormone therapy for the management of postmenopausal women

Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part I

Should hormone replacement therapy (any route of administration) be considered in all postmenopausal women with lower urinary tract symptoms? Report from the ICI‐RS 2023

Knowledge, attitudes and management strategies in Scandinavia concerning hormone replacement therapy: a comparison between gynecologists in Denmark, Norway and Sweden

Quality improvement project - Reducing the inadvertent prescribing of unopposed estrogen in primary care Dr Liz Horrocks Banstead PCN

The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women

Hormonal therapies and venous thrombosis: Considerations for prevention and management

Hormone replacement therapy in the menopause

Exploring the Feasibility of Estrogen Replacement Therapy as a Treatment for Perimenopausal Depression: A Comprehensive Literature Review

British Menopause Society consensus statement: The risks and benefits of HRT before and after a breast cancer diagnosis

Determinants of long-term hormone replacement therapy and reasons for early discontinuation